TheTechno Optimist.

Plozasiran (Redemplo)Arrowhead Pharmaceuticals—Health Canada issues Notice of Compliance for Redemplo (plozasiran) for familial chylomicronemia syndromePlozasiran (Redemplo)Arrowhead Pharmaceuticals—FDA approves Redemplo (plozasiran) for familial chylomicronemia syndromePlozasiran (Redemplo)Arrowhead Pharmaceuticals—China NMPA approves Redemplo (plozasiran) for familial chylomicronemia syndrome; Sanofi to commercialize

Plozasiran (Redemplo)

by Arrowhead PharmaceuticalsUS

siRNA targeting APOC3, which blocks triglyceride clearance. Approved for familial chylomicronemia; in Phase 3 for severe hypertriglyceridemia.

DeployStage 4 of 5

FDA-approved for FCS (Nov 2025); Phase 3 in severe hypertriglyceridemia.

Updated Jan 2026Checked 10 Oct0 updates this week

Milestones

Next · Phase 3 in severe hypertriglyceridemia (sHTG)
  1. Phase 3 PALISADE meets primary and key secondary endpoints2024Complete.
  2. FDA approval for familial chylomicronemia syndrome (FCS)Nov 2025Complete.
  3. China NMPA approval for FCS (in partnership with Sanofi)Jan 2026Complete.
  4. Health Canada approval for FCS2026Complete.
  5. Phase 3 in severe hypertriglyceridemia (sHTG)Target 2026Current milestone.

Most important updates

Upcoming

  1. 2026Phase 3 in severe hypertriglyceridemia (sHTG) (next)
  2. 2027Phase 3 readout for severe hypertriglyceridemia
Primer